Peter Altman, CEO of BioCardia Inc. (NASDAQ: BCDA), executed his largest direct stock purchase, acquiring shares valued at $5,550 at an average price of $1.11 each. Disclosed on April 29, 2026, the transaction boosted his ownership by 5,000 shares, elevating his direct holdings to 280,766 shares.
BCDA shares currently hover near the 52-week low of $1.00, reflecting an 8% drop over the past day and a 64% decline over the past year.
Financial Results and Clinical Progress
BioCardia released its fourth-quarter 2025 financial results, showing slight rises in expenses and losses due to ongoing clinical program advancements.
The company channels resources into the CardiAMP cell therapy via key collaborations, capitalizing on strong clinical results and precise mechanisms of action.
FDA Data Submission
BioCardia submitted CardiAMP HF trial data to the U.S. Food and Drug Administration to strengthen the case for CardiAMP system approval. Officials aim to resolve previous clinical holds through detailed surrogate endpoint data for heart failure treatments under conditional approval guidelines.
Japan PMDA Breakthrough Status
Japan’s Pharmaceuticals and Medical Devices Agency granted breakthrough therapy designation to the CardiAMP cell therapy. Regulators plan focused reviews on safety and essential aspects of the CardiAMP Sepa cell therapy.
While evaluating foreign trial data and therapy components, PMDA requires supplementary post-approval studies within Japan.
Advanced Imaging Software Launch
BioCardia showcased unique capabilities of its Heart3D Fusion Imaging software, tailored for accurate cell delivery in cardiac interventions and noninvasive domestic uses.
These initiatives highlight expanded research efforts, drawing attention from engineering investors.
